SCHEMBL26728043

SCHEMBL26728043

CC(C)N1C2CCC1CC(C(=O)O)C2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ENPP2 Q13822 5/20 0.36
LPAR1 Q92633 1/20 0.35
POLB P06746 1/20 0.33
DUSP3 P51452 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.32
CYP2C9 P11712 1/20 0.32
APLNR P35414 1/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
TSHR P16473 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23475160 1.00 MAPT (0.40) MAPTTDP1MEN1KMT2AENPP2
SCHEMBL26997591 0.83 LMNA (0.32) TDP1LMNACYP2C9
SCHEMBL21145976 0.82 SMN1; SMN2 (0.37) ALDH1A1LMNACYP2C9
SCHEMBL17716574 0.81 MEN1 (0.33) MAPTTDP1MEN1KMT2ADUSP3
SCHEMBL8947045 0.80 LMNA (0.52) TDP1MEN1KMT2AALDH1A1LMNA
SCHEMBL11388564 0.80 LMNA (0.52) TDP1MEN1KMT2AALDH1A1LMNA
SCHEMBL21145996 0.79 CHRNB2 (0.43)
Hydrochloric Acid SCHEMBL2417970 0.78 TDP1 (0.52) TDP1MEN1KMT2AALDH1A1LMNA
SCHEMBL26488863 0.77 MAPT (0.41) MAPTKMT2APOLBAPLNR
SCHEMBL761441 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018150-A1 SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF ARROMAX PHARMATECH CO., LTD. (CN) 2024-01-18 US disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS MAPT 3235/4885TDP1 69/4885MEN1 1514/4885
US-20240018150-A1 SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF BTK, SYK, LCK MAPT 2529/4885TDP1 673/4885MEN1 1463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.